Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Research & Development (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Research & Development for 13 consecutive years, with $116.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 353.32% to $116.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $388.5 million, a 64.13% increase, with the full-year FY2025 number at $388.5 million, up 64.13% from a year prior.
  • Research & Development was $116.3 million for Q4 2025 at Madrigal Pharmaceuticals, down from $174.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $174.0 million in Q3 2025 to a low of $25.6 million in Q4 2024.
  • A 5-year average of $67.4 million and a median of $65.2 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 63.69% in 2024, then soared 353.32% in 2025.
  • Madrigal Pharmaceuticals' Research & Development stood at $52.9 million in 2021, then skyrocketed by 33.76% to $70.7 million in 2022, then decreased by 0.14% to $70.6 million in 2023, then tumbled by 63.69% to $25.6 million in 2024, then skyrocketed by 353.32% to $116.3 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Research & Development are $116.3 million (Q4 2025), $174.0 million (Q3 2025), and $54.1 million (Q2 2025).